Roche

News

Roche adds to pipeline with Poseida, Kiniksa deals

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases.

News

Conceptual image of a head with cog gears as brain.

AC Immune tries to resurrect crenezumab with new data delve

In May, another amyloid targeting drug for Alzheimer's disease – AC Immune and Roche's crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so

Oncology

Oncology market dominance: As easy as ADC?

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals.

News

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...

Roche's Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulat

News

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its

News

Roche CEO Severin Schwan to stand down after 14 years

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group.

Roche adds to pipeline with Poseida, Kiniksa deals

AC Immune tries to resurrect crenezumab with new data delve

Oncology market dominance: As easy as ADC?

Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche CEO Severin Schwan to stand down after 14 years

NICE changes stance on Genmab's cervical cancer drug

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks